O	0	9	Rationale
O	10	13	and
O	14	20	design
O	21	23	of
O	24	27	the
O	28	45	Multidisciplinary
O	46	54	Approach
O	55	57	to
O	58	63	Novel
O	64	73	Therapies
O	74	76	in
O	77	87	Cardiology
O	88	96	Oncology
O	97	105	Research
O	106	111	Trial
O	112	113	(
O	113	122	MANTICORE
O	123	126	101
O	126	127	-
O	127	128	-
O	128	134	Breast
O	134	135	)
O	135	136	:
O	137	138	a
O	139	149	randomized
O	149	150	,
O	151	158	placebo
O	158	159	-
O	159	169	controlled
O	170	175	trial
O	176	178	to
O	179	188	determine
O	189	191	if
O	192	204	conventional
B-intervention	205	210	heart
I-intervention	211	218	failure
I-intervention	219	234	pharmacotherapy
O	235	238	can
O	239	246	prevent
B-condition	247	258	trastuzumab
I-condition	258	259	-
I-condition	259	267	mediated
I-condition	268	272	left
I-condition	273	284	ventricular
I-condition	285	295	remodeling
O	296	301	among
O	302	310	patients
O	311	315	with
O	316	320	HER2
O	320	321	+
O	322	327	early
O	328	334	breast
O	335	341	cancer
O	342	347	using
O	348	355	cardiac
O	356	359	MRI
O	359	360	.

O	361	370	MANTICORE
O	371	374	101
O	375	376	-
O	377	383	Breast
O	384	385	(
O	385	402	Multidisciplinary
O	403	411	Approach
O	412	414	to
O	415	420	Novel
O	421	430	Therapies
O	431	433	in
O	434	444	Cardiology
O	445	453	Oncology
O	454	462	Research
O	462	463	)
O	464	466	is
O	467	468	a
O	469	479	randomized
O	480	485	trial
O	486	488	to
O	489	498	determine
O	499	501	if
O	502	514	conventional
O	515	520	heart
O	521	528	failure
O	529	544	pharmacotherapy
O	545	546	(
O	546	557	angiotensin
O	558	568	converting
O	569	575	enzyme
O	576	585	inhibitor
O	586	588	or
O	589	593	beta
O	593	594	-
O	594	601	blocker
O	601	602	)
O	603	606	can
O	607	614	prevent
O	615	626	trastuzumab
O	626	627	-
O	627	635	mediated
O	636	640	left
O	641	652	ventricular
O	653	663	remodeling
O	663	664	,
O	665	673	measured
O	674	678	with
O	679	686	cardiac
O	687	690	MRI
O	690	691	,
O	692	697	among
O	698	706	patients
O	707	711	with
O	712	716	HER2
O	716	717	+
O	718	723	early
O	724	730	breast
O	731	737	cancer
O	737	738	.

B-total-participants	739	742	One
I-total-participants	743	750	hundred
I-total-participants	751	754	and
I-total-participants	755	760	fifty
I-total-participants	760	761	-
I-total-participants	761	765	nine
B-eligibility	766	774	patients
I-eligibility	775	779	with
I-eligibility	780	794	histologically
I-eligibility	795	804	confirmed
I-eligibility	805	809	HER2
I-eligibility	809	810	+
I-eligibility	811	817	breast
I-eligibility	818	824	cancer
O	825	829	will
O	830	832	be
O	833	841	enrolled
O	842	844	in
O	845	846	a
O	847	855	parallel
O	856	857	3
O	857	858	-
O	858	861	arm
O	861	862	,
O	863	873	randomized
O	873	874	,
O	875	882	placebo
O	883	893	controlled
O	893	894	,
O	895	901	double
O	901	902	-
O	902	907	blind
O	908	914	design
O	914	915	.

O	916	921	After
O	922	930	baseline
O	931	942	assessments
O	942	943	,
O	944	956	participants
O	957	961	will
O	962	964	be
O	965	975	randomized
O	976	978	in
O	979	980	a
O	981	982	1
O	982	983	:
O	983	984	1
O	984	985	:
O	985	986	1
O	987	992	ratio
O	993	995	to
O	996	998	an
O	999	1010	angiotensin
O	1010	1011	-
O	1011	1021	converting
O	1022	1028	enzyme
O	1029	1038	inhibitor
O	1039	1040	(
O	1040	1051	perindopril
O	1051	1052	)
O	1052	1053	,
O	1054	1058	beta
O	1058	1059	-
O	1059	1066	blocker
O	1067	1068	(
O	1068	1078	bisoprolol
O	1078	1079	)
O	1079	1080	,
O	1081	1083	or
B-control	1084	1091	placebo
O	1091	1092	.

O	1093	1105	Participants
O	1106	1110	will
O	1111	1118	receive
O	1119	1123	drug
O	1124	1126	or
O	1127	1134	placebo
O	1135	1138	for
O	1139	1140	1
O	1141	1145	year
O	1146	1155	beginning
O	1156	1157	7
O	1158	1162	days
O	1163	1169	before
O	1170	1181	trastuzumab
O	1182	1189	therapy
O	1189	1190	.

O	1191	1198	Dosages
O	1199	1202	for
O	1203	1206	all
O	1207	1213	groups
O	1214	1218	will
O	1219	1221	be
O	1222	1236	systematically
O	1237	1239	up
O	1239	1240	-
O	1240	1248	titrated
O	1248	1249	,
O	1250	1252	as
O	1253	1262	tolerated
O	1262	1263	,
O	1264	1266	at
O	1267	1268	1
O	1269	1273	week
O	1274	1283	intervals
O	1284	1287	for
O	1288	1289	a
O	1290	1295	total
O	1296	1298	of
O	1299	1300	3
O	1301	1306	weeks
O	1306	1307	.

O	1308	1311	The
O	1312	1319	primary
O	1320	1329	objective
O	1330	1332	of
O	1333	1337	this
O	1338	1348	randomized
O	1349	1357	clinical
O	1358	1363	trial
O	1364	1366	is
O	1367	1369	to
O	1370	1379	determine
O	1380	1382	if
O	1383	1395	conventional
O	1396	1401	heart
O	1402	1409	failure
O	1410	1425	pharmacotherapy
O	1426	1429	can
O	1430	1437	prevent
O	1438	1449	trastuzumab
O	1449	1450	-
O	1450	1458	mediated
O	1459	1463	left
O	1464	1475	ventricular
O	1476	1486	remodeling
O	1487	1492	among
O	1493	1501	patients
O	1502	1506	with
O	1507	1511	HER2
O	1511	1512	+
O	1513	1518	early
O	1519	1525	breast
O	1526	1532	cancer
O	1532	1533	,
O	1534	1536	as
O	1537	1545	measured
O	1546	1548	by
B-outcome-Measure	1549	1551	12
I-outcome-Measure	1552	1557	month
I-outcome-Measure	1558	1564	change
I-outcome-Measure	1565	1567	in
I-outcome-Measure	1568	1572	left
I-outcome-Measure	1573	1584	ventricular
I-outcome-Measure	1585	1588	end
I-outcome-Measure	1588	1589	-
I-outcome-Measure	1589	1598	diastolic
I-outcome-Measure	1599	1605	volume
O	1606	1611	using
O	1612	1619	cardiac
O	1620	1623	MRI
O	1623	1624	.

O	1625	1634	Secondary
O	1635	1645	objectives
O	1646	1653	include
O	1654	1655	1
O	1655	1656	)
O	1657	1666	determine
O	1667	1670	the
B-outcome-Measure	1671	1680	evolution
I-outcome-Measure	1681	1683	of
I-outcome-Measure	1684	1688	left
I-outcome-Measure	1689	1700	ventricular
I-outcome-Measure	1701	1711	remodeling
I-outcome-Measure	1712	1714	on
I-outcome-Measure	1715	1722	cardiac
I-outcome-Measure	1723	1726	MRI
O	1727	1729	in
O	1730	1738	patients
O	1739	1743	with
O	1744	1748	HER2
O	1748	1749	+
O	1750	1755	early
O	1756	1762	breast
O	1763	1769	cancer
O	1769	1770	,
O	1771	1772	2
O	1772	1773	)
O	1774	1784	understand
O	1785	1788	the
O	1789	1798	mechanism
O	1799	1801	of
O	1802	1813	trastuzumab
O	1814	1822	mediated
O	1823	1830	cardiac
O	1831	1839	toxicity
O	1840	1842	by
O	1843	1852	assessing
O	1853	1856	for
O	1857	1860	the
B-outcome-Measure	1861	1869	presence
I-outcome-Measure	1870	1872	of
I-outcome-Measure	1873	1883	myocardial
I-outcome-Measure	1884	1890	injury
I-outcome-Measure	1891	1894	and
I-outcome-Measure	1895	1904	apoptosis
I-outcome-Measure	1905	1907	on
I-outcome-Measure	1908	1913	serum
I-outcome-Measure	1914	1924	biomarkers
I-outcome-Measure	1925	1928	and
I-outcome-Measure	1929	1936	cardiac
I-outcome-Measure	1937	1940	MRI
O	1940	1941	,
O	1942	1945	and
O	1946	1947	3
O	1947	1948	)
B-outcome-Measure	1949	1958	correlate
I-outcome-Measure	1959	1966	cardiac
I-outcome-Measure	1967	1977	biomarkers
I-outcome-Measure	1978	1980	of
I-outcome-Measure	1981	1988	myocyte
I-outcome-Measure	1989	1995	injury
I-outcome-Measure	1996	1999	and
I-outcome-Measure	2000	2005	extra
I-outcome-Measure	2005	2006	-
I-outcome-Measure	2006	2014	cellular
I-outcome-Measure	2015	2021	matrix
I-outcome-Measure	2022	2032	remodeling
I-outcome-Measure	2033	2037	with
I-outcome-Measure	2038	2042	left
I-outcome-Measure	2043	2054	ventricular
I-outcome-Measure	2055	2065	remodeling
I-outcome-Measure	2066	2068	on
I-outcome-Measure	2069	2076	cardiac
I-outcome-Measure	2077	2080	MRI
O	2081	2083	in
O	2084	2092	patients
O	2093	2097	with
O	2098	2102	HER2
O	2102	2103	+
O	2104	2109	early
O	2110	2116	breast
O	2117	2123	cancer
O	2123	2124	.

O	2125	2132	Cardiac
O	2133	2141	toxicity
O	2142	2144	as
O	2145	2146	a
O	2147	2153	result
O	2154	2156	of
O	2157	2163	cancer
O	2164	2173	therapies
O	2174	2176	is
O	2177	2180	now
O	2181	2191	recognized
O	2192	2194	as
O	2195	2196	a
O	2197	2208	significant
O	2209	2215	health
O	2216	2223	problem
O	2224	2226	of
O	2227	2237	increasing
O	2238	2248	prevalence
O	2248	2249	.

O	2250	2252	To
O	2253	2256	our
O	2257	2266	knowledge
O	2266	2267	,
O	2268	2277	MANTICORE
O	2278	2282	will
O	2283	2285	be
O	2286	2289	the
O	2290	2295	first
O	2296	2306	randomized
O	2307	2312	trial
O	2313	2320	testing
O	2321	2327	proven
O	2328	2333	heart
O	2334	2341	failure
O	2342	2357	pharmacotherapy
O	2358	2360	in
O	2361	2364	the
O	2365	2375	prevention
O	2376	2378	of
O	2379	2390	trastuzumab
O	2390	2391	-
O	2391	2399	mediated
O	2400	2414	cardiotoxicity
O	2414	2415	.

O	2416	2418	We
O	2419	2425	expect
O	2426	2429	the
O	2430	2438	findings
O	2439	2441	of
O	2442	2446	this
O	2447	2452	trial
O	2453	2455	to
O	2456	2463	provide
O	2464	2473	important
O	2474	2482	evidence
O	2483	2485	in
O	2486	2489	the
O	2490	2501	development
O	2502	2504	of
O	2505	2515	guidelines
O	2516	2519	for
O	2520	2530	preventive
O	2531	2538	therapy
O	2538	2539	.

O	2540	2554	ClinicalTrials
O	2554	2555	.
O	2555	2558	gov
O	2558	2559	:
O	2560	2571	NCT01016886
O	2571	2572	.
